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Methods for the immunological detection of Bacillus anthracis in various environmental samples and 
the discrimination of B. anthracis from other members of the B. cereus group are not yet well 
established. To generate specific discriminating antibodies, we immunized rabbits, mice, and chickens 
with inactivated B. anthracis spores and, additionally, immunized rabbits and mice with the 
tetrasaccharide ß-Ant–(1→3)-α-LRhap–( 1→3)- α -L-Rhap–(1→2)-L-Rhap. It is a constituent of the 
exosporium glycoprotein BclA and contains the newly discovered sugar anthrose 2-O-methyl-4-(3-
hydroxy-3-methylbutamido)-4,6-dideoxy-ß-D-glucose. The BclA protein is a major component of the 
exosporium of B. anthracis spores and is decorated by the tetrasaccharide indicated above. The 
anthrose-containing tetrasaccharide chain seems to be highly specific for B. anthracis, which makes it 
a key biomarker for the detection of these spores. The different immunizations led to anthrose-reactive 
polyclonal and monoclonal antibodies which were analyzed by various methods to characterize their 
ability to discriminate between B. anthracis and other Bacillus spp. Multiple applications, such as 
enzyme-linked immunosorbent assay, indirect immunofluorescence assay, and electron microscopy, 
revealed the specificities of the polyclonal and monoclonal antibodies generated for B. anthracis spore 
detection. All polyclonal antibodies were able to correctly identify the B. anthracis strains tested and 
showed only minimal cross-reactivities with other Bacillus strains. Moreover, the antibodies generated 
proved functional in a new capture assay for B. anthracis spores and could therefore be useful for the 

































Bacillus anthracis, the causative agent of anthrax, is a rodshaped, gram-positive bacillus. Whenever 
vegetative cells of B. anthracis are deprived of nutrients, spores are formed. These spores are highly 
resistant to any kind of environmental condition and can remain viable for years (25). Once they enter 
a susceptible host, like herbivores or humans, they start to germinate and multiply (24), causing a 
severe disease with a high mortality rate. Three distinct layers enclosing the core of the spore and 
housing the genome of the bacterium are the main constituents that provide protection from damage. 
These layers include a cortex of peptidoglycan, a proteinaceous coat, and a loosely fitting exosporium 
(9, 22). The B. anthracis exosporium serves as a semipermeable barrier against large, potentially 
harmful molecules such as antibodies and hydrolytic enzymes (8). The major component of the 
exosporium is the glycoprotein BclA (bacillus collagen-like protein of anthracis) (10, 27, 34), which 
contains multiple, collagen-like Xaa-Yaa- Gly (or XXG) repeats in its central region (34). BclA is highly 
immunogenic (32) and plays an important role in the association of the spore with human extracellular 
matrix proteins (2).  
 
Daubenspeck and colleagues described the identification of two oligosaccharides attached to BclA, a 
715-Da tetrasaccharide and a 324-Da disaccharide, and showed that multiple copies of the O-linked 
tetrasaccharide are attached to several sites within the central collagen-like region of BclA (6).  
 
The tetrasaccharide ß-Ant–(133)-α-L-Rhap–(133)- α -L–Rhap– (132)-L-Rhap contains a unique sugar 
residue, 2-O-methyl-4-(3- hydroxy-3-methylbutamido)-4,6-dideoxy-ß-D-glucose, termed anthrose. The 
synthesis of the anthrose-containing tetrasaccharide, alone and in conjugation with carrier proteins, 
has been carried out by several groups (4, 23, 30, 39) and has also been used for vaccination 
experiments (23, 37). It was shown that the immunization of animals with these antigens induces 
antibodies that specifically bind to B. anthracis spores (23, 36, 37). However, most of these antibodies 
also showed crossreactivities with other members of the B. cereus group (36). Because of the 
potential use of B. anthracis as a terrorist weapon, the Centers for Disease Control and Prevention 
(CDC; Atlanta, GA) categorized this pathogen as a category A agent with the highest hazardous 
potential. When the mail system was used for biological attacks in the United States in 2001, the great 
efficacy of this pathogen to infect many people when it was intentionally distributed became visible 
(16). In addition to PCR techniques, which could be hampered by inhibitory factors, and inefficient 
means for the preparation of DNA from spores, the rapid immunological detection of B. anthracis from 
complex specimens is currently possible only when the spore concentrations are relatively high and 
when handheld test kits are used (12). In cases of lower concentrations, time-consuming cultivation 
and later identification would take too long in an emergency situation (11). Thus, there is a crucial 
need for a sensitive and highly specific means of identification of B. anthracis spores in environmental 
samples that urgently need to be tested. However, accurate detection can be problematic due to 
cross-reactive Bacillus spp. From the environment (7). These circumstances make it necessary to 
learn more about the spore components appropriate for the reliable detection of these pathogens (14). 
Despite this, the anthrose tetrasaccharide seems to be a promising marker for use in the development 
of new, specific, and sensitive detection assays. 
To verify the presence of B. anthracis spores in environmental and suspect samples, we raised 
polyclonal and monoclonal antibodies against the anthrose tetrasaccharide and B. anthracis spores by 
applying different approaches. We were able to show the specificities of these antibodies for their 
reactions to different B. anthracis strains and their ability to distinguish between pathogenic and 
nonpathogenic Bacillus spp. using the tetrasaccharide for discrimination. In the capture enzymelinked 
immunosorbent assay (ELISA), our antibodies showed no cross-reactivity to other members of the B. 

















Materials and Methods 
 
Preparation and inactivation of bacteria.  
 
Bacterial strains (Table 1) were cultivated on appropriate nutrient media under adequate safety 
conditions. Except for strains obtained from strain collections, the sources of these strains were 
described previously (20). The sources of strains from strain collections are indicated in Table 1. To 
acquire highly resistant spores, cultures were stored at room temperature (RT) for 3 to 4 weeks, and 
colony material was inoculated in 1 ml 0.85% NaCl. For inactivation, 9 ml of 1% peracetic acid (PAA)–
80% ethanol was added for 30 min at RT. The cells were centrifuged at 4,000 x g for 15 min, and the 
pellet was washed twice with 10 ml aqua bidest. Finally, the pellet was resuspended in 1 ml 0.85% 
NaCl, and the sterility was verified by cultivation of an aliquot under optimal growth conditions for 2 to 
3 weeks. Afterwards, the cell count was determined by using an improved Neubauer counting 
chamber.  
Additionally, inactivation with paraformaldehyde (PFA) was done essentially as described for PAA 
inactivation by using 4% PFA in phosphate-buffered saline (PBS; pH 7.4). Cells were directly 
inoculated in 1 ml PFA for 1 h and centrifuged, and the pellet was resuspended in 10% PFA–0.05% 
glutaraldehyde for 12 to 15 h at RT. Centrifugation and washing of the cells as well as sterility testing 




Desalting of commercial KLH.  
 
Keyhole limpet hemocyanin (KLH; 20 mg; product no. H 7017; Sigma-Aldrich, Taufkirchen, Germany) 
was dissolved in 10 mM ammonium carbonate and dialyzed against the same solvent (eight times) by 
using a 30,000-molecular-weight-cutoff filter Amicon Ultra Millipore centrifugal device and an 
Eppendorf centrifuge (4,000 rpm, 4°C). The retentate was filtered through a 0.22-mm-pore-size Millex 
syringe filter and lyophilized, resulting in desalted KLH (18 mg). 
 
 
Conjugation of desalted KLH with the squaric acid derivative of the anthrax tetrasaccharide.  
 
Because of the inhomogeneity and high molecular mass of KLH, it was impossible to set up the 
conjugation experiment and monitor the conjugation reaction by surface-enhanced laser desorption 
ionization–time-offlight mass spectrometry (3, 31) to yield a conjugate with a predetermined KLH-
carbohydrate ratio. Guided by the results of our recent study (13), the conjugation was set up as 
follows.  
The desalted KLH (18 mg) was dissolved by vortexing in a borate buffer (0.5 M, pH 9.0, ~300 ml); 1 
mg of the tetrasaccharide squarate, which was prepared as described previously (29), was added; and 
the mixture was stirred overnight. The conjugation mixture was then desalted as described above for 
the commercial KLH. The retentate consisted of a soluble part and a jelly part, which were 
separated. Freeze-drying of the soluble part provided material (9 mg) that was dissolved in PBS and 
used to coat the ELISA plates, as described below. Freezedrying of the jelly part resulted in a white 
solid material (8 mg) which was not examined further. 
 
 
Conjugation of BSA with the squaric acid derivative of the anthrax tetrasaccharide. 
 
The conjugation experiment was conducted with a hapten concentration of 40 mmol and was set up to 
yield a conjugate with a carbohydrate-protein ratio of approximately 6:1. To compensate for the 
hydrolysis of some of the squarate derivative during conjugation, the initial carbohydrate-bovine serum 
albumin (BSA) ratio was 7:1. Accordingly, BSA (30 mg, 0.00045 mM; product no. A0281; Sigma-
Aldrich) was dissolved in borate buffer (0.5 M, 80 ml, pH 9.0), the tetrasaccharide (3.1 mg, 0.00315 
mM) (29) was added, and the mixture was stirred for 28 h, when surface-enhanced laser desorption 
ionization–time-offlight mass spectrometry showed a hapten-onto-protein loading proportion of 6.4. 
Borate buffer (0.05 M, pH 7.0, 1 ml) was added, and the mixture was desalted as described above. 
Filtration through a 0.22-mm-pore-size Millex syringe filter and freeze-drying resulted in the conjugate, 





Immunization of animals.  
 
All work with animals was done and registered in compliance with the German animal protection law. 
Rabbits (chinchilla hybrid) were immunized either with the anthrose-BSA conjugate (Fig. 1B) or with 
PAA-inactivated B. anthracis spores. Additionally, one chicken (White leghorn) was immunized 
intramuscularly with B. anthracis spores in a way similar to that in which the rabbits were immunized. 
The first immunization consisted of 250 μg antigen or 106 spores in 100 μl in Freund’s complete 
adjuvant (Sigma-Aldrich). The next three booster immunizations were administered at intervals of 2 
weeks (4 weeks for the chicken), and each booster immunization consisted of 125 μg antigen in 
Freund’s incomplete adjuvant (Sigma-Aldrich). The number of spores used for the booster 
immunizations was the same in all cases. After the third boost, the rabbits were bled (20 ml) and 
serum was separated for investigation by ELISA and affinity chromatography. Eggs were collected 
from the chicken 10 days after each booster immunization, and immunoglobulin Y (IgY) was separated 
from the egg yolk, as described previously (26).  
Five 8-week-old female BALB/c mice were immunized with the free anthrose tetrasaccharide (Fig. 1A), 
and additionally, another five mice were injected with the inactivated spores used for the rabbits and 
the chicken, as described above. Each subcutaneous immunization consisted of 50 μg carbohydrate 
in lipopeptide adjuvant (EMC Microcollections GmbH, Tuebingen, Germany) or 106 spores/ml in 
Freund’s complete adjuvant or Freund’s incomplete adjuvant and was done according to the 
manufacturer’s instructions. The mice were immunized six times at intervals of 2 weeks. Although the 
antibody titer in the mice was relatively low (1:1,000) for anthrose immunization, spleen cells were 
used to generate monoclonal antibodies by use of the hybridoma technology. Cell fusion with the 
myeloma cell line P3X63Ag8 (18), cloning by limiting dilution, and the selection procedures were done 
as described previously (21). Screening of the culture supernatants was done by ELISA on BSA-
conjugated anthrose or the soluble part of KLH-conjugated anthrose. After the subcloning and 
rescreening of selected hybridomas, the classes, subclasses, and light chains of the antibodies were 
determined with an IsoStrip kit (Roche, Indianapolis, IN), according to the manufacturer’s instructions. 
 
 
Affinity chromatography.  
 
Polyclonal antianthrose rabbit serum (pc115) was first purified from BSA-reactive antibodies by the 
use of BSA-coupled N-hydroxysuccinimide (NHS)-activated Sepharose. In brief, 2.5 mg of BSA 
(Sigma- Aldrich) solubilized in 0.1 M NaHCO3–0.5 M NaCl (pH 8.3) was coupled to HiTrap NHS-
activated Sepharose (Amersham/GE Healthcare, Munich, Germany) according to the manufacturer’s 
instructions. After coupling of the BSA, 5 to 10 ml serum was incubated with the generated BSA-
Sepharose for 1 h at RT to bind to the BSA antibodies. The column was washed with 30 to 50 ml PBS, 
and for reuse, the bound antibodies were eluted with 0.1 M glycine, pH 3.0, in 1-ml steps until the 
absorbance was nearly 0. Twenty microliters of 1.5 M Tris-HCl, pH 8.8, was used to neutralize the 
eluted antibodies. However, one step of purification was not sufficient to remove all BSA-reactive 
antibodies. Following the anti-BSA purification, IgG was purified via protein G-Sepharose 4 fast flow 
(Amersham/GE Healthcare), according to the manufacturer’s instructions. Polyclonal serum from the 
spore-immunized rabbit (pc114) was purified only via protein G-Sepharose, as described above. 
 
 
Immunological tests.  
 
(I) Anthrose ELISA.  
 
ELISA on anthrose-BSA or anthrose- KLH conjugates for screening was performed essentially as 
described elsewhere (15). In brief, flat-bottomed 96-well polystyrene plates (MaxiSorp; Nunc, 
Wiesbaden, Germany) were coated by passive absorption with 50 μl/well anthrose conjugate at 1.0 
μg/ml in 0.1Mcarbonate buffer, pH 9.6, for 2 h at 37°C or overnight (o/n) at 4°C. After the plates were 
washed three times with PBS (pH 7.4) containing 0.05% Tween 20 (PBS-T), the wells were blocked 
with 75 μl block/dilution buffer containing 10% goat serum in PBS-T for 60 min at 37°C. After the 
plates were washed three times, 50 μl of primary antibodies in block/ dilution buffer or undiluted 
culture supernatants from hybridoma cells were added to duplicate wells for 1 h at 37°C. The wells 
were washed three times, and 50 μl of goat anti-rabbit horseradish peroxidase (HRPO)-conjugated 
secondary antibody, goat anti-mouse IgG/IgM HRPO-conjugated secondary antibody, or rabbit anti-
chicken HRPO-conjugated secondary antibody (all from Dianova, Hamburg, Germany) were added at 
0.4 μg/ml for 1 h at 37°C. The wells were washed with 300 μl PBS-T five times, bound antibodies were 
detected by adding 200 μl of o-phenylendiamine (Sigma-Aldrich) as the substrate, and the reaction 
  
was stopped after 10 min by addition of 50 μl 2.5 M sulfuric acid. The optical density (OD) values at 
492 nm (OD492) (reference wavelength, 620 nm) were then recorded with a Sunrise plate reader 
(Tecan Instruments, Crailsheim, Germany) interfaced with a computer. Samples were considered 




(IIi) Spore ELISA.  
 
The spore ELISA was performed essentially as described elsewhere (5). In brief, flat-bottomed 96-well 
polystyrene plates (MaxiSorp; Nunc) were coated by passive absorption with 100 μl/well of an 
inactivated bacterial preparation at a concentration of 1 X 106/ml in 0.1 M NaHCO3 buffer, pH 9.6, o/n 
at 4°C. After the plates were washed three times with PBS-T, the wells were blocked with 100 μl 4% 
skim milk powder in PBS-T for 30 min at 37°C. After these washing steps, antibodies diluted in 1% 
skim milk powder in PBS-T were added in duplicate wells for 1 h at 37°C. Further steps were 
performed as described above for the anthrose ELISA. 
 
 
(III) Capture spore ELISA.  
 
For the capture spore ELISA, 100 μl/well of polyclonal antianthrose pc115 or pc114 spore antibody (at 
5 μg/ml each) was used to coat flat-bottomed 96-well polystyrene plates (MaxiSorp; Nunc) in 0.1 M 
NaHCO3 buffer, pH 9.6, for 2 h at 37°C or o/n at 4°C. After washing and blocking of the wells with 
10% goat serum (Invitrogen, Karlsruhe, Germany) for 60 min at 37°C, plates with either pc115-
biotinylated antibody (at 1.25 μg/ml in blocking buffer), pc114-biotinylated antibody (at 2.5 μg/ml in 
block buffer), or a pool of IgY antibodies against B. anthracis spores (H64-BA IgY; 1:750 in blocking 
buffer) in duplicate wells were incubated. Biotinylation of pc115 and pc114 was done with an EZ-Link 
sulfo-NHS-biotin labeling kit (Pierce/Perbio, Bonn, Germany), according to the manufacturer’s 
instructions. After the plates were washed, 100 μl/well of a streptavidin-HRPO conjugate (1 μg/ml) or 
HRPOlabeled goat anti-chicken secondary antibody (0.4 μg/ml) (both from Dianova) was added and 
development occurred as described above. Samples were considered positive when they showed an 
OD greater than the mean for the blank (n = 6) plus 3 SDs. The coefficient of variation (CV; in percent) 
for all ELISAs was calculated by use of the equation (σ/μ) · 100, where σ is the SD and μ is the mean. 
 
 
(IV) IFA.  
 
For the indirect immunofluorescence assay (IFA), 10 μl of PAAinactivated bacteria (106/ml) was 
placed on 10-field immunofluorescence slides (BioMe´rieux, Marcy I’Etoile, France). The slides were 
dried for 1 to 2 h at RT, fixed with ice-cold methanol for 15 min or 4% PFA–PBS for 20 min, and 
blocked with 5% goat serum (Invitrogen) in 1% BSA–PBS for 30 min at RT. For double staining, 25 μl  
of polyclonal antianthrose antibody pc115 at 0.25 μ g/ml and monoclonal BclA antibody EG4-4, kindly 
provided by J. Kearney (33), at 0.5 μ g/ml was added; and the mixture was incubated for 30 min at 
37°C. After the slides were washed, PBS-Alexa 594-conjugated secondary goat anti-rabbit antibody 
and Alexa 488-conjugated goat anti-mouse antibody (both from Molecular Probes, Karlsruhe, 
Germany) were added for 30 min at 37°C and the slides were then washed with PBS. Culture 
supernatants of mouse monoclonal antibodies were used at 1:2 to 1:5 dilutions. Secondary goat anti-
mouse Alexa 488-conjugated antibody (Molecular Probes) was used for detection. A pool of polyclonal 
spore antibody H64-BA IgY was used at a 1:8,000 dilution, and detection by the use of goat anti-
chicken Alexa 488-conjugated secondary antibody (Molecular Probes) followed. All secondary 
detection antibodies were used at a 1:300 dilution. Mounting was done with Prolong Gold Antifade 
plus 4,6-diamidino-2- phenylindole (DAPI; Molecular Probes), according to the manufacturer’s 
instructions, and the preparations were examined by fluorescence microscopy.  
Data were acquired with an AxioCam MR camera (Zeiss) driven by Axiovision software (version 4.4; 









(V) Immunoelectron microscopy.  
 
Preparations of PAA-inactivated B. anthracis spores were washed with HEPES buffer (0.05 M, pH 7.2) 
and adsorbed on alcian blue-coated cover slides. To prevent unspecific binding, spores were treated 
with blocking buffer (0.05% BSA, 0.1% gelatin in PBS) for 30 min. Subsequently, the primary antibody 
or undiluted antiserum was applied for 1 h at RT. Polyclonal anthrose antibody pc115 and an 
unspecific rabbit serum against Francisella tularensis (Becton Dickinson), which was used as a 
negative control, were used at a concentration of 0.7 μ g/ μ l. Next, five washing steps with blocking 
buffer followed, and a goat anti-rabbit antibody conjugated with 10-nm-diameter gold (diluted 1:50 in 
blocking buffer; Amersham) was added for 1 h at RT. After the washing steps, a second fixation with 
2.5% glutaraldehyde in 0.05% HEPES buffer was applied and the slides were rinsed with aqua bidest. 
The spores were then treated with an increasing ethanol concentration and infiltrated with 
hexamethyldisilazane (Sigma-Aldrich). The air-dried preparation was carbon coated (BAE 250; Leica) 
and inspected with a LEO 1530 scanning electron microscope (Zeiss) by using in-lens secondary 









We immunized BALB/c mice with the free anthrose tetrasaccharide in combination with a lipopeptide 
adjuvant previously developed for use for immunization with haptens (1). Mice were also immunized 
with PAA-inactivated B. anthracis spores. After the fusion of spleen cells with mouse myeloma cells, 
screening of the supernatants from wells with growing hybridomas was done by ELISA with a 
tetrasaccharide-KLH conjugate on the solid phase. Five reactive monoclonal antibodies from mice 
immunized with the anthrose-containing tetrasaccharide and one from mice immunized with spores 
were chosen for limiting dilution, and in addition to anthrose reactivity, subclones were tested for 
positive signals for the PAAinactivated B. anthracis spores by ELISA (Fig. 2, right). The supernatants 
of all subclones showed reactivity with the anthrose- KLH conjugate as well as inactivated B. anthracis 
spores. The results for the three selected subclones indicated in Table 2 and Fig. 2 are representative 
of those for the other subclones that screened positive.  
 
Immunization with the anthrose conjugate led to the development of specific polyclonal antibodies in 
rabbits. Interestingly, in addition to the generation of antibodies in mice, hightiter antianthrose 
antibodies were also generated in rabbits and a chicken by immunization with spores from B. 
anthracis, indicating that anthrose is an immunodominant component of the spore. Figure 2 shows the 
reactivities of polyclonal antibody pc115 in an ELISA with the anthrose-KLH conjugate and inactivated 
B. anthracis CDC 1014 spores compared to the reactivities of polyclonal spore antibodies pc114 and 
H64-BA IgY (Fig. 2, left) and the monoclonal antibodies against the free tetrasaccharide anthrose and 
B. anthracis spores (Fig. 2, right). KLH alone served as a negative control and raised no signals 
against the antibodies. BSA and the BSA-anthrose conjugate were not used to coat the ELISA plates, 
since immunization of the rabbit had occurred with this conjugate and such an ELISA could have false-
positive results. The spore antibodies pc114, H64-BA IgY, and F7-1D3 were as reactive with the 
tetrasaccharide as with the spores, showing signal intensities similar to the signal intensity of the 
pc115 anthrose-induced antibody. This indicates a strong antibody response against anthrose when 
the animals were immunized with PAA-inactivated B. anthracis spores. The CV for this assay varied 
from 2.7% to 18.8%. Furthermore, we tested the specificity of the polyclonal antibodies for different 
Bacillus spp. and gram-negative strains (Table 1). For the safe handling of pathogenic B. anthracis 
and B. cereus strains outside a biosafety level 3 or 2 
facility, we tested PAA and PFA for their abilities to inactivate such strains. In previous experiments we 
had already evaluated different inactivation methods that still allowed the best possible binding of 
antibodies. Those experiments revealed that treatment with PAA or PFA may be applied but still 
preserve epitope recognition by most antibodies (data not shown). Table 3 summarizes the results of 
the spore ELISA with the pc115, pc114, and H64-BA IgY antibodies for different strains. Positive 
results were given by an OD492 greater than the mean for the blank (n = 6) plus three times the SD. 
The pc115 and pc114 antibodies recognized spores of B. anthracis inactivated by the use of both the 
method with PAA and the method with PFA (data not shown), with identical results being achieved. 
H64-BA IgY showed stronger signals with PAA-inactivated bacteria. Moreover, all polyclonal 
antibodies were able to discriminate between B. anthracis and non-B. anthracis strains of the genus 
  
Bacillus. By ELISA, the pc115 anthrose antibody showed cross-reactivity with B. cereus strain 2617; 
the pc114 spore antibody showed cross-reactivity with B. cereus strains ATCC 10987, ATCC 14579, 
Hohenheim, and 2617; and the H64-BA IgY antibody also showed cross-reactivity only with B. cereus 
strain 2617. None of the other Bacillus spp. or gramnegative bacteria was reactive with the polyclonal 
antibodies.  
 
To develop a specific assay for the detection of B. anthracis spores from complex probes, we 
determined the suitability of all polyclonal antibodies in the capture ELISA either as a coating antibody 
or as a detection antibody. pc115 was able to serve as the coating and detection antibody by using 
direct biotinylation or HRPO conjugation of the antibody. pc114 showed characteristics similar to those 
of pc115 and also functioned as a capture antibody as well as a detection antibody in combination with 
the pc115 anthrose antibody. H64-BA IgY was useful for detection with both pc115 or pc114 as the 
capture antibody. We tested the specificity and the sensitivity of this capture ELISA for the detection of 
B. anthracis spores. Table 1 provides the mean values from five independent experiments (SD = 
0.013, CV = 13.1%) for testing of the specificity of the pc115 antibody as the capture antibody and the 
detection antibody (biotinylated). The blank used for subtraction in this assay was the no-antigen 
control. The cross-reactivity with one B. cereus strain seen before by the spore ELISA was not 
apparent by the capture ELISA, resulting in a 100% specificity for B. anthracis spores. Weak OD 
signals, such as those observed for B. cereus strain A-049 and the B. thuringiensis serovar konkukian 
strain, occurred only at high spore concentrations (≥106/ml) and were absent within one lower log 
stage of bacteria (data not shown). To circumvent such false-positive results, a serial dilution of a 
standard was always tested. Figure 3 shows the use of the above-mentioned combinations of different 
antibody pairs for coating and detection (shown for strain CDC 1014 in Fig. 3). The limit of detection 
(LOD) was calculated from the OD492 of the mean for the blank from four independent experiments 
plus three times the SD as the threshold (the line in Fig. 3). The CV was calculated by use of the 
means and SDs of the values from four independent experiments. For the pc115-biotinylated pc115 
antibody pair, the LOD was >0.34 (CV = 13.1%), which corresponds to 1 X 104 to 3 X 104 spores/ml, 
for the pc115-biotinylated pc114 antibody pair it was >0.42 (CV = 12%), and for the pc115– H64-BA 
IgY antibody pair it was >0.23 (CV = 3.8%), which corresponds to 1 X 104 spores/ml (Fig. 3A). pc114 
in combination with biotinylated pc115 gave an LOD of >0.25 (CV = 10.8%), and pc114 in combination 
with H64-BA IgY as the detector gave an LOD of >0.18 (CV = 4.4%), indicating that it was the most 
sensitive pair (4 X 103 spores/ml, Fig. 3B), but this pair must be investigated in more detail for its 
specificity. The testing of the other B. anthracis strains (Table 1) revealed no difference in the resulting 
LODs. The analysis of new monoclonal antibodies for use in the capture assay is still in progress.  
 
In the IFA, polyclonal antibody pc115 (Fig. 4A) stained clearly visible ring structures around the spores 
of inactivated B. anthracis spores. Double staining with a monoclonal BclA antibody (EG4-4; a kind gift 
from J. Kearney) (Fig. 4B) revealed the colocalization of BclA and anthrose on the spores (Fig. 4C). 
The visualization of cell nuclei by using DAPI (Fig. 4C and F) or phase-contrast microscopy (data not 
shown) revealed no signal on the vegetative cells by use of the pc115 antibody. In contrast, additional 
but weak staining of vegetative cells was observed with the pc114 (data not shown) or H64-BA IgY 
(Fig. 4E) spore antibody. Spore antibodies pc114 and H64-BA IgY showed only minor cross-
reactivities with four and two B. cereus strains, respectively, which is comparable to the results of the 
ELISA presented in Table 3. In the IFA, the monoclonal antibodies showed patterns of staining of 
PFA-inactivated B. anthracis spores identical to those shown by polyclonal anthrose antibody pc115 
(data not shown). Interestingly, by double staining with pc115, the 
monoclonal and polyclonal antibodies competed in their binding to the spore; some spores were 
stained only with the monoclonal antibody and some were stained only with the polyclonal antibody 
(data not shown).  
 
Additionally, we showed the reactivity of the polyclonal pc115 antibody to the anthrose exosporium 
component by electron microscopy, visualized by an immunogold-labeled secondary antibody that 
clearly localized within the exosporium structures of PAA-inactivated B. anthracis spores (Fig. 5A). 
The arrows in Fig. 5A indicate positively stained B. anthracis spores. Preimmune serum from rabbits 
immunized with anthrose- BSA (Fig. 5B) and unspecific rabbit serum (Fig. 5C) were not reactive with 
the B. anthracis spores. The results obtained by the use of a mixture of B. anthracis spores (uneven 
surface) and B. subtilis spores (smooth surface) also underlines the specificity of the anthrose 
antibody (Fig. 5D, arrow), since no gold particles could be observed on the surfaces of the B. subtilis 
spores. Bacteria were also visualized by using corresponding in-lens secondary electron detection to 






Antibodies against the tetrasaccharide anthrose are a suitable tool for use for the detection of B. 
anthracis spores. Different approaches lead to anthrose-reactive polyclonal and monoclonal 
antibodies: immunization with an anthrose-BSA conjugate, with free anthrose, and with PAA-
inactivated B. anthracis spores. The antibodies described in this study were tested for their 
specificities and their abilities to be included in a specific and sensitive detection assay. Tamborrini et 
al. (36) generated antibodies against the tetrasaccharide showing cross-reactivities with other 
members of the B. cereus group. Our pc115 polyclonal anthrose antibody was cross-reactive with only 
one B. cereus strain by ELISA and IFA. This crossreactivity was not observed by the capture ELISA. 
No crossreactivities with other Bacillus strains or gram-negative bacteria suspected of being agents of 
bioterrorism were seen. Thus, our polyclonal anthrose antibody showed 100% specificity for B. 
anthracis spores. Furthermore, we were able to show the colocalization of the pc115 anthrose 
antibody with the anti- BclA antibody EG4-4 on the surface of B. anthracis spores by IFA, underlining 
the glycosylation of BclA with the tetrasaccharide and correct epitope recognition of our new antibody. 
The false-positive reactivity with KLH could be excluded by ELISA (Fig. 2). More studies are in 
progress to apply the monoclonal and polyclonal anthrose antibodies to the detection of B. anthracis in 
complex matrices containing interfering contaminants or carrier substances which could potentially 
inhibit the reaction or be cross-reactive.  
 
Confirming the findings of other studies (38), we were able to show that the high degree of antigenicity 
of BclA also raised high levels of anthrose in spore-immunized animals (Fig. 2). Both polyclonal 
antibodies, pc114 and H64-BA IgY, as well as the monoclonal antibodies generated against 
inactivated B. anthracis spores, showed reactivities against the anthrose conjugates, indicating the 
conservation of the sugar on PAA-inactivated spores. 
 
The generation of polyclonal and monoclonal antibodies using the tetrasaccharide anthrose as the 
target antigen was effected to develop highly sensitive immunological assays for the detection of B. 
anthracis. Such assays have not been well described before. Besides PCR-based detection, only a 
few immunological detection systems, such as lateral-flow immunoassays, are available, but they offer 
detection limits that range from only 105 to 106 spores/ml (12, 19). Unfortunately, no information on 
the target antigens of the antibodies used in those assays is available. With our capture ELISA with 
the anthrose tetrasaccharide as the target antigen, we were able to detect 1 X 104 to 5 X 104 
spores/ml. Therefore, the sugar coat on the B. anthracis spore surface is an ideal indicator for spore 
detection. The newly generated polyclonal spore antibodies are also a useful and sensitive tool for use 
in combination with the anthrose antibody in the capture ELISA.  
 
As shown by Brahmbhatt and colleagues (2), BclA acts as a shield to reduce early spore germination 
and decreases the association with the human extracellular matrix proteins laminin and fibronectin. In 
this context, anthrose may play a role in the infection of the host cell. The binding of host cells to 
carbohydrates is often found during the defense against a pathogen (17, 35). Anthrose could act as a 
key component in the attachment of the spore to the host cell surface. Similar glycosylated and highly 
immunogenic proteins were found in Mycobacterium tuberculosis (28).  
 
Like Dong and colleagues (8), we found that strains of the B. cereus group, for example, B. cereus 
strain 2617, carried the anthrose operon in their sequences (data not shown). For strain 2617, cross-
reactivities with the anthrose antibodies generated occurred by direct ELISA and IFA. They were 
absent by the capture ELISA, suggesting that the strain has lower levels of anthrose on the spore 
surface or has sugar residues structurally similar to but not identical to those of B. anthracis spores. 
Other strains may also contain the anthrose operon in their genomes but fail to transcribe this specific 
sugar residue. The sequence is perhaps not intact and is therefore not transcribed, or the strains are 
not able to produce anthrose but instead produce a different sugar residue as a modification, but we 
failed to detect such a sugar residue with our antibodies.  
 
The methods used in this study, in which PAA and PFA were applied to inactivate spores, showed no 
differences in the binding behaviors of the polyclonal and monoclonal anthrose antibodies, although 
immunization was carried out with the native anthrose-BSA conjugate and anthrose tetrasaccharide. 
These methods allow the rapid inactivation of samples containing unknown agents so that potentially 
infectious material does not need to be handled for testing by diagnostic assays. Irradiation, which 
also preserves the epitope, is not applicable for use for rapid diagnosis (5). Since the inactivation of 
spores by the use of either PAA or PFA is based on different chemistries, they may have diverse 
influences on the conservation of the epitope. Comparison of the polyclonal antibodies showed no 
  
difference between the two inactivation methods. By ELISA, the monoclonal antibodies showed 
stronger signals with PFA-inactivated cells and reacted by IFA only when PFA was used for fixation. 
This indicates that the tetrasaccharide has different binding sites which could easily be destroyed or 
masked by the use of various inactivation or fixation methods.  
 
We describe here the production and characterization of polyclonal and monoclonal antibodies against 
the exosporium tetrasaccharide anthrose. With our capture ELISA for the immunological detection of 
B. anthracis spores, we have a rapid and sensitive tool with a detection limit lower than the detection 
limits of most commercially available assays (11). The specificity and the sensitivity of the pc115 
antibody in the capture ELISA in combination with polyclonal spore antibodies pc114 and H64-BA IgY 
make it a conclusive and reliable 
tool for the application and the development of new detection assays. Therefore, the basis for the 
introduction of the generated antibodies into other detection platforms for the easy and rapid discovery 
of B. anthracis by the use of complex probes has been created. The inhibitory properties of the 
antibodies generated here and the inhibition of the ELISA by the free tetrasaccharide, as shown 
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Figures and Tables 
 
Table 1. Specificity testing of capture ELISA with pc115 as the capture antibody and biotinylated 
pc115 as the detection antibody 
  
 






Table 3. Summary of reactivities of polyclonal anthrose and spore antibodies against PAA-inactivated 




Figure 1. Structures of the synthetic tetrasaccharide side chain of BclA (A) and the conjugate 
immunogen (B) prepared from it and BSA used for immunization of the animals and the generation of 
antibodies. Me, methyl. 
 
 
Figure 2. Reactivities of polyclonal (left) and monoclonal (right) anthrose and spore antibodies with the 
anthrose-KLH conjugate and PAAinactivated B. anthracis CDC 1014 spores, as determined by ELISA. 
Coating with KLH was used as a negative control. The antibodies were used at different dilutions. ODs 
were measured at a wavelength of 492 nm. Values are means ± SDs of five independent experiments. 
The antianthrose antibodies were pc115, F6-2ID6, and F6-2IIG3; the antispore antibodies were pc114, 





Figure 3. Sensitivity of capture ELISA by the use of pc115 (A) or pc114 (B) for coating. Different 
concentrations of PAA-inactivated B. anthracis CDC 1014 spores were detected with biotinylated 
pc115 antibody (pc115-biot.), biotinylated pc114 antibody (pc114-biot.), or H64-BA IgY using 
the indicated concentrations and dilutions. ODs were measured at a wavelength of 492 nm. All values 
are means ± SDs of at least four independent experiments. Lines indicate the LODs of the polyclonal 
antibodies used for detection calculated by use of the mean for the blank (i.e., the no-antigen control) 








Figure 4. Immunofluorescence staining of B. anthracis using polyclonal antibodies against anthrose 
and spores. Inactivated B. anthracis spores were stained with polyclonal anthrose antibody pc115 (A) 
and were visualized with a goat anti-rabbit Alexa 594-labeled secondary antibody. Colocalization with 
the BclA protein (B) was shown by using monoclonal BclA antibody EG4-4, detected with goat anti-
mouse Alexa 488-labeled antibody. The overlapping of the staining of pc115 and EG4-4 appears 
yellow and is shown as a merged image (D). The H64-BA IgY polyclonal spore antibody (E) was 
visualized by using goat antichicken Alexa 488-labeled detection antibody. The presence of spores 
was observed by phase-contrast microscopy (data not shown), and cell nuclei were stained with DAPI 
(C and F). Note the staining only of spores and not of vegetative cells in the case of the anthrose and 



































Figure 5. Immunoelectron micrographs (backscattered electron detection) of pc115 (A), preserum of a 
rabbit immunized with anthrose-BSA (B), and unspecific rabbit serum (C) on PAA-inactivated B. 
anthracis spores detected with gold-labeled secondary antibody. (D) Immunostaining with pc115 on a 
mixture containing B. anthracis spores and B. subtilis spores. (A to D) In-lens secondary electron 
detection of the immune staining corresponding to panels A to D, respectively. Arrows, anthrose-
positive B. anthracis spores. Magnification, X150,000. 
 
 
  
